AMGN US0311621009

Report

Delayed Nasdaq - 12/03 04:00:00 pm
202.44	USD		+0.63%

12/03	AMGEN : Bradway Hails Amgen's Progress Against 'Undruggable' Disease Targets at Two Healthcare Forums	PU
12/03	Amgen Raises Fiscal Q1 Dividend 10% to $1.94 a Share, Payable March 8 to Shareholders of Record Feb. 15	MT
12/03	Amgen Announces 10% Increase In 2022 First Quarter Dividend	PR

Company

Business Summary

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Number of employees : 24 300 people.

Sales per Business

	2019		2020		Delta
Human Therapeutics	22 204.00	95.5%	24 240.00	96%	+9.17%
Other	1 158.00	5%	1 184.00	4.7%	+2.25%
USD in Million

Sales per region

	2019		2020		Delta
United States	17 224.00	74%	18 496.00	73.3%	+7.39%
Rest of the World	5 962.00	25.6%	6 787.00	26.9%	+13.84%
Canada	176.00	0.8%	141.00	0.6%	-19.89%
USD in Million

Managers

Name	Title	Age	Since
Robert Bradway	Chairman, President & Chief Executive Officer	57	-
Peter Griffith	Chief Financial Officer & Executive Vice President	61	2020
David Reese	Executive Vice President-Research & Development	57	2018
Darryl Sleep	Chief Medical Officer & Senior VP-Global Medical	-	2018
Mike Zahigian	Chief Information Officer & Senior Vice President	-	2017
Saptarsi Haldar	VP-Research & Head-Cardiometabolic Disorders	-	-
Esteban Santos	Executive Vice President-Operations	52	2016
Nancy Grygiel	Chief Compliance Officer	52	2020
Ronald Sugar	Independent Director	72	2011
Tyler E. Jacks, Dr.	Independent Director	59	2012

Members of the board

Name	Title	Age	Since
Robert Bradway	Chairman, President & Chief Executive Officer	57	-
Ronald Sugar	Independent Director	72	2011
Tyler E. Jacks, Dr.	Independent Director	59	2012
Robert Eckert	Lead Independent Director	65	2012
Greg Garland	Independent Director	62	2013
Robert Sanders Williams, Dr.	Independent Director	71	2014
Ellen Kullman	Independent Director	64	2016
Charles M. Holley	Independent Director	63	2017
Wanda M. Austin, Dr.	Independent Director	65	2017
Brian J. Druker, Dr.	Independent Director	64	2018

Equities

	Vote	Quantity	Free-Float		Company-owned shares		Total Float
Stock A	1	563,265,902	562,062,880	99.8%	0	0.0%	99.8%

Shareholders

Name	Equities	%
Capital Research & Management Co.	71,504,200	12.6%
The Vanguard Group, Inc.	44,336,367	7.81%
SSgA Funds Management, Inc.	29,641,701	5.22%
Capital Research & Management Co. (Global Investors)	26,724,181	4.71%
PRIMECAP Management Co.	16,082,687	2.83%
BlackRock Fund Advisors	12,466,871	2.20%
NWQ Investment Management Co. LLC	11,762,842	2.07%
Geode Capital Management LLC	10,362,110	1.82%
Morgan Stanley Smith Barney LLC (Investment Management)	8,388,102	1.48%
Sands Capital Management LLC	8,360,926	1.47%

Holdings

Name	Equities	%	Valuation
BEIGENE, LTD. (6160)	246,269,426	20.3%	6,895,120,345 USD
AKERO THERAPEUTICS, INC. (AKRO)	1,508,375	4.32%	32,414,979 USD
IMAGO BIOSCIENCES, INC. (IMGO)	1,193,047	3.57%	31,758,911 USD
JASPER THERAPEUTICS, INC. (JSPR)	2,700,000	7.39%	24,651,000 USD
PROVENTION BIO, INC. (PRVB)	2,500,000	3.94%	15,650,000 USD
BEIGENE, LTD.	246,269,426	20.2%	2,463 USD

Markets and indexes

- International Market

- Nasdaq 100 / S&P 100, S&P 500, Stoxx Americas 100, Stoxx Global 200, Stoxx NorthAmerica 50, Stoxx USA 50

Company contact information

Amgen Inc.
1 Amgen Center Drive
CA 91320-1799 Thousand Oaks, California

Phone : +1 805 447 1000
Fax : +1 805 447 1010
web site : https://investors.amgen.com/